Volume 120, Issue 4, Pages (March 2001)

Slides:

Advertisements

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Celiac disease–like abnormalities in a subgroup of patients with irritable bowel syndrome Ulrich Wahnschaffe, R. Ullrich, E.O. Riecken, J.D. Schulzke Gastroenterology.

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Interleukin 15 mediates epithelial changes in celiac disease Luigi Maiuri, Carolina Ciacci, Salvatore Auricchio, Virginia Brown, Sonia Quaratino, Marco.

Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice Debra G. Silberg, Jessica Sullivan, Eugene Kang, Gary P. Swain, Jennifer.

It's time to bring the best and brightest back to gastroenterology!

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gerald Holtmann*,

Volume 68, Issue 5, Pages (November 2005)

Volume 119, Issue 4, Pages (October 2000)

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects Paolo L. Peghini, Philip O. Katz, Donald.

Michael Charlton, Bo Ahlman, K.Sreekumaran Nair Gastroenterology

Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface- Induced Eicosanoid Production Knut Tore Lappegård, MD, Johan Riesenfeld,

Volume 122, Issue 3, Pages (March 2002)

First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori Stephan Timm, Marco Sailer, Karl–hermann.

Diagnosis of irritable bowel syndrome

Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis Guadalupe.

Lawrence K. Gates, Dawn V. Holladay Gastroenterology

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? William E. Whitehead, Olafur.

Gastric cancer, cytotoxin-associated gene A–positive Helicobacter pylori, and serum pepsinogens: An international study Penelope M. Webb, Jean E. Crabtree,

In vivo absorption of medium-chain fatty acids by the rat colon exceeds that of short- chain fatty acids Jimmy R. Jørgensen, Mark D. Fitch, Per B. Mortensen,

Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick

Volume 123, Issue 6, Pages (December 2002)

Psychiatric disorders among veterans with hepatitis C infection

Volume 124, Issue 4, Pages (April 2003)

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis Friedrich Horak, MD, Kamal D.

Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families Paul D.P. Pharoah,

Hepatitis B infection in heart transplant recipients

Evaluation and Treatment of Obesity

Craig Mowat, Andrew Carswell, Angela Wirz, Kenneth E.L. McColl

Appendectomy is followed by increased risk of Crohn's disease

Volume 123, Issue 2, Pages (August 2002)

Volume 115, Issue 1, Pages (July 1998)

Volume 120, Issue 3, Pages (February 2001)

Volume 150, Issue 4, Pages (April 2016)

Volume 121, Issue 4, Pages (October 2001)

Volume 120, Issue 4, Pages (March 2001)

William K. Fackler, Tina M. Ours, Michael F. Vaezi, Joel E. Richter

Severe Constipation Clinical Gastroenterology and Hepatology

Volume 151, Issue 1, Pages e6 (July 2016)

Grace J. Young, BA, Nicole Harter, MD, Minnelly Luu, MD

Michael Charlton, Bo Ahlman, K.Sreekumaran Nair Gastroenterology

Volume 123, Issue 1, Pages (July 2002)

Volume 120, Issue 7, Pages (June 2001)

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

AGA technical review on nonalcoholic fatty liver disease

AGA technical review on celiac sprue

Volume 114, Issue 6, Pages (June 1998)

Psychiatric disorders among veterans with hepatitis C infection

Volume 123, Issue 5, Pages (November 2002)

Volume 124, Issue 4, Pages (April 2003)

Image of the month Gastroenterology

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gerald Holtmann*,

Abnormalities of Prostaglandins and Cyclooxygenase Enzymes in Female Patients With Slow-Transit Constipation Ping Cong, Victor Pricolo, Piero Biancani,

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study Clare Atherton, John Jones,

Volume 122, Issue 3, Pages (March 2002)

Volume 119, Issue 4, Pages (October 2000)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 116, Issue 5, Pages (May 1999)

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

Prostaglandin E2 and aggressive factors increase the gland luminal pressure in the rat gastric mucosa in vivo Ingrid Synnerstad, Lena Holm Gastroenterology

The North American Study for the Treatment of Refractory Ascites

Volume 122, Issue 5, Pages (May 2002)

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects Paolo L. Peghini, Philip O. Katz, Donald.

Volume 120, Issue 4, Pages (March 2001)

Volume 123, Issue 6, Pages (December 2002)

Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma Kameran Daham, MD, PhD, Anna James, PhD,

Volume 4, Issue 3, Pages (March 2018)

Volume 120, Issue 4, Pages (March 2001)

Presentation transcript:

Volume 120, Issue 4, Pages 867-873 (March 2001) Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production Nicholas J. Wight, Keith Gottesdiener, Nigel M. Garlick, Clare T. Atherton, Sue Novak, Barry J. Gertz, Nicole A. Calder, J. Cote, P. Wong, Amy Dallob, Chris J. Hawkey Gastroenterology Volume 120, Issue 4, Pages 867-873 (March 2001) DOI: 10.1053/gast.2001.22432 Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 1 Diagram of the scheme used when taking 12 mucosal biopsy specimens from the gastric antrum at the end of each treatment period. Care was taken to ensure that specimens were taken from different sites in each study period. Gastroenterology 2001 120, 867-873DOI: (10.1053/gast.2001.22432) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 2 Gastric mucosal PGE2 synthesis rates (pg · mg−1 · min−1) determined ex vivo after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between-subject SE). Each subject's gastric PGE2 synthesis value was an average over 12 gastric mucosal biopsy specimens. Gastroenterology 2001 120, 867-873DOI: (10.1053/gast.2001.22432) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 3 The percent change from baseline in LPS-stimulated PGE2 production in whole blood after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between subject SE). Gastroenterology 2001 120, 867-873DOI: (10.1053/gast.2001.22432) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 4 The percent change from baseline in serum-generated TXB2 in whole blood after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between-subject SE). Gastroenterology 2001 120, 867-873DOI: (10.1053/gast.2001.22432) Copyright © 2001 American Gastroenterological Association Terms and Conditions